Express News | Ultragenyx Pharmaceutical Inc : JP Morgan Raises Target Price to $105 From $94
BofA Securities Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $73
Ultragenyx Pharmaceutical: A Strong Buy on Rare Disease Program Progress and Strategic Management
RARE's Bone Disorder Drug Gets FDA's Breakthrough Therapy Tag
Ultragenyx Pharmaceutical's Bone Disease Drug Gets FDA's Breakthrough Therapy Designation
Express News | Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (Ux143) in Osteogenesis Imperfecta